Ion-channel assay technologies: quo vadis?

Abstract:

:Although many existing methods are used to study the functions of ion channels and to screen lead compounds for important ion-channel targets, new technologies are being developed for improved performance. It is important to identify the advantages and disadvantages of each technology. In this review, we segment the ion-channel assay market according to distinguishable applications, and compare the needs of each market segment with the capabilities of different technologies in terms of multiple assay attributes. We further discuss the future directions in the development of ion-channel assays.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Xu J,Wang X,Ensign B,Li M,Wu L,Guia A,Xu J

doi

10.1016/s1359-6446(01)02095-5

subject

Has Abstract

pub_date

2001-12-15 00:00:00

pages

1278-1287

issue

24

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(01)02095-5

journal_volume

6

pub_type

杂志文章
  • Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

    abstract::In therapeutic areas aimed at developing an orally administered drug, the pharmacokinetic profile of a drug candidate after oral administration in vivo is pivotal in evaluating its success. This can be done by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01299-9

    authors: Cox KA,Dunn-Meynell K,Korfmacher WA,Broske L,Nomeir AA,Lin CC,Cayen MN,Barr WH

    更新日期:1999-05-01 00:00:00

  • Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.

    abstract::Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation. In moderate-to-severe COPD, long-acting bronchodilators are the basis of therapy. Inhaled long-acting β(2)-agonists (LABAs) are used for the treatment of COPD. LABAs have been in use since the 1990s enabling persistent bro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.11.002

    authors: Malerba M,Radaeli A,Morjaria JB

    更新日期:2012-05-01 00:00:00

  • Targeting VEGF-neuropilin interactions: a promising antitumor strategy.

    abstract::Inhibition of vascular endothelial growth factor (VEGF) or its corresponding receptor (VEGFR) has been validated as an efficacious antiangiogenetic approach for cancer treatment. More recently, neuropilins (NRPs), the essential coreceptors for VEGF, have also been shown to have a significant role in VEGF signaling. Gi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.10.004

    authors: Peng K,Bai Y,Zhu Q,Hu B,Xu Y

    更新日期:2019-02-01 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • The use of gene-specific IgY antibodies for drug target discovery.

    abstract::Genomics and gene expression data require interpretation at the protein level to validate the biological or pathological findings. To match with the efficiency and capacity of DNA microarray application, methods and approaches of protein analysis in multiplex and high-throughput manner are required for effectively dis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(03)02655-2

    authors: Zhang WW

    更新日期:2003-04-15 00:00:00

  • WITHDRAWN: Enabling infrastructure for global health product development.

    abstract::This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2012.05.014

    authors: Satcher R,Evans-Storms RB

    更新日期:2012-06-01 00:00:00

  • Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins.

    abstract::Cervical cancer is the fourth most common cancer among women worldwide and its development is mainly associated with human papillomavirus infection, a highly sexually transmissible virus. The expression of E6 and E7 viral oncoproteins deregulates cell repairing mechanisms through impairment of tumor suppressor protein...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.07.011

    authors: Almeida AM,Queiroz JA,Sousa F,Sousa Â

    更新日期:2019-10-01 00:00:00

  • Filtering promiscuous compounds in early drug discovery: is it a good idea?

    abstract::The use of computational filters for excluding supposedly nonspecific and promiscuous compounds from chemical libraries is a controversial issue, because many drugs used in clinics today would never reach the market if these filters were applied. In part, this conflict could be caused by the paradigm: one-drug-one-tar...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.02.004

    authors: Senger MR,Fraga CA,Dantas RF,Silva FP Jr

    更新日期:2016-06-01 00:00:00

  • Immunoinformatics: current trends and future directions.

    abstract::Immunoinformatics has recently emerged as a critical field for accelerating immunology research. Although still an evolving process, computational models now play instrumental roles, not only in directing the selection of key experiments, but also in the formulation of new testable hypotheses through detailed analysis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.04.001

    authors: Tong JC,Ren EC

    更新日期:2009-07-01 00:00:00

  • Functionalizing bioinks for 3D bioprinting applications.

    abstract::3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.012

    authors: Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

    更新日期:2019-01-01 00:00:00

  • Pancreatic lipase inhibitors from natural sources: unexplored potential.

    abstract::The prevalence of obesity is increasing at an alarming rate, but, unfortunately, only a few medications are currently on the market. Obesity is primarily regarded as a disorder of lipid metabolism and the enzymes involved in this process could be selectively targeted to develop antiobesity drugs. Recently, newer appro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.07.024

    authors: Birari RB,Bhutani KK

    更新日期:2007-10-01 00:00:00

  • Light-triggerable formulations for the intracellular controlled release of biomolecules.

    abstract::New therapies based on the use of biomolecules [e.g., proteins, peptides, and non-coding (nc)RNAs] have emerged during the past few years. Given their instability, adverse effects, and limited ability to cross cell membranes, delivery systems are required to fully reveal their biological potential. Sophisticated nanof...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.01.019

    authors: Lino MM,Ferreira L

    更新日期:2018-05-01 00:00:00

  • 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR.

    abstract::The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters. 3D structures for the ligand-binding domain (LBD) of these receptors are abundantl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.01.001

    authors: Wu B,Li S,Dong D

    更新日期:2013-06-01 00:00:00

  • Molecular perspectives on solid-state phase transformation and chemical reactivity of drugs: metoclopramide as an example.

    abstract::Here, I provide an overview of the solid-state characteristics, phase transformations and chemical reactions of metoclopramide hydrochloride monohydrate (MCP HCl H2O). Three unique techniques, including thermoanalytical methods, one-step simultaneous differential scanning calorimetry (DSC) and Fourier transform infrar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.10.001

    authors: Lin SY

    更新日期:2015-02-01 00:00:00

  • Drugs affecting glycosaminoglycan metabolism.

    abstract::Glycosaminoglycans (GAGs) are charged polysaccharides ubiquitously present at the cell surface and in the extracellular matrix. GAGs are crucial for cellular homeostasis, and their metabolism is altered during pathological processes. However, little consideration has been given to the regulation of the GAG milieu thro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.05.010

    authors: Ghiselli G,Maccarana M

    更新日期:2016-07-01 00:00:00

  • Surrogate approaches in development of monoclonal antibodies.

    abstract::When cross-reactivity of a lead antibody across species is limited, antibody development programs require the generation of surrogate molecules or surrogate animal models necessary for the conduct of preclinical pharmacology and safety studies. When surrogate approaches are employed, the complexities and challenges fo...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.09.014

    authors: Bornstein GG,Klakamp SL,Andrews L,Boyle WJ,Tabrizi M

    更新日期:2009-12-01 00:00:00

  • Snapshot PK: a rapid rodent in vivo preclinical screening approach.

    abstract::Described in this article are strategies implemented to increase the throughput of in vivo rodent pharmacokinetic (PK) studies using the snapshot PK study design and automated methods for compound submission, sample processing, data analysis and reporting. Applying snapshot PK studies to categorize the oral exposure o...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.10.014

    authors: Liu B,Chang J,Gordon WP,Isbell J,Zhou Y,Tuntland T

    更新日期:2008-04-01 00:00:00

  • Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation.

    abstract::In recent years there has been a dramatic increase in the number of freely accessible online databases serving the chemistry community. The internet provides chemistry data that can be used for data-mining, for computer models, and integration into systems to aid drug discovery. There is however a responsibility to en...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.013

    authors: Williams AJ,Ekins S,Tkachenko V

    更新日期:2012-07-01 00:00:00

  • Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

    abstract::Cancer is the second highest cause of death worldwide. Several therapeutic approaches, such as conventional chemotherapy, antibodies and small molecule inhibitors and nanotherapeutics have been employed in battling cancer. Amongst them, nanotheranostics is an example of successful personalized medicine bearing dual ro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.08.009

    authors: Nabil G,Bhise K,Sau S,Atef M,El-Banna HA,Iyer AK

    更新日期:2019-02-01 00:00:00

  • Current progress in antivascular tumor therapy.

    abstract::The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and p...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.06.001

    authors: Ho YJ,Wang TC,Fan CH,Yeh CK

    更新日期:2017-10-01 00:00:00

  • Molecular epigenetic targets for liver diseases: current challenges and future prospects.

    abstract::Advanced chemotherapy fails to treat liver cancer but recent progress in understanding epigenetic modifications have witnessed promising clinical outcomes. Epigenetic alteration is the alteration of epigenomes (surrounding histone proteins) without changing the DNA sequence. Such epigenetic mechanisms include histone ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.07.008

    authors: Zeidler R,de Freitas Soares BL,Bader A,Giri S

    更新日期:2017-11-01 00:00:00

  • Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders.

    abstract::The choroid plexus (CP) is a highly vascularized organ located in the brain ventricles and contains a single epithelial cell layer forming the blood-cerebrospinal fluid barrier (BCSFB). This barrier is crucial for immune surveillance in health and is an underestimated gate for entry of immune cells during numerous inf...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.05.003

    authors: Demeestere D,Libert C,Vandenbroucke RE

    更新日期:2015-08-01 00:00:00

  • The design, structures and therapeutic potential of protein epitope mimetics.

    abstract::Using a biologically relevant peptide or protein structure as a starting point for lead identification represents one of the most powerful approaches in modern drug discovery. Here, we focus on the protein epitope mimetic (PEM) approach, where folded 3D structures of peptides and proteins are taken as starting points ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.07.008

    authors: Robinson JA,Demarco S,Gombert F,Moehle K,Obrecht D

    更新日期:2008-11-01 00:00:00

  • Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.

    abstract::Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be bene...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03512-9

    authors: Hofmann F,García-Echeverría C

    更新日期:2005-08-01 00:00:00

  • Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications.

    abstract::Stimulation of bone regeneration using growth factors is a promising approach for musculoskeletal regenerative engineering. However, common limitations with protein growth factors, such as high manufacturing costs, protein instability, contamination issues, and unwanted immunogenic responses of the host reduce potenti...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.01.012

    authors: Laurencin CT,Ashe KM,Henry N,Kan HM,Lo KW

    更新日期:2014-06-01 00:00:00

  • Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives.

    abstract::Opinions about the therapeutic efficacy of medicinal herbs differ significantly. Some reported herbal efficacies at low doses of active ingredients suggest a need for investigating whether these are because of placebo or multi-ingredient synergistic effects. This review discusses the opinions, methods and outcomes of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.03.012

    authors: Ma XH,Zheng CJ,Han LY,Xie B,Jia J,Cao ZW,Li YX,Chen YZ

    更新日期:2009-06-01 00:00:00

  • Targeting fatty acid metabolism in heart failure: is it a suitable therapeutic approach?

    abstract::The energy substrate preference of the human heart is well regulated and is modified upon aging, in that the fetal heart uses glucose, whereas the adult heart utilizes fatty acids. Various human and animal studies suggest a shift in myocardial substrate utilization and decreased rate of myocardial fatty acid uptake an...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.02.010

    authors: Arumugam S,Sreedhar R,Thandavarayan RA,Karuppagounder V,Watanabe K

    更新日期:2016-06-01 00:00:00

  • Recent computational advances in the identification of allosteric sites in proteins.

    abstract::Allosteric modulators have the potential to fine-tune protein functional activity. Therefore, the targeting of allosteric sites, as a strategy in drug design, is gaining increasing attention. Currently, it is not trivial to find and characterize new allosteric sites by experimental approaches. Alternatively, computati...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.07.012

    authors: Lu S,Huang W,Zhang J

    更新日期:2014-10-01 00:00:00

  • Pharmaceutical patents: reconciling the human right to health with the incentive to invent.

    abstract::In developed countries that protect core aspects of the fundamental human right to the highest attainable standard of health, how does that right intersect with intellectual property rights? Here, the human rights implication of providing access to all cancer drugs recommended by experts in a developed country is cons...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.04.009

    authors: Khachigian LM

    更新日期:2020-07-01 00:00:00

  • Chemoproteomics-driven drug discovery: addressing high attrition rates.

    abstract::The advent of multiple high-throughput technologies has brought drug discovery round almost full circle, from pharmacological testing of compounds in vivo to engineered molecular target assays and back to integrated phenotypic screens in cells and organisms. In the past, primary screens to identify new pharmacological...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.04.014

    authors: Hall SE

    更新日期:2006-06-01 00:00:00